Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia

Leuk Lymphoma. 2020 Sep;61(9):2271-2273. doi: 10.1080/10428194.2020.1761965. Epub 2020 May 19.

Authors

Jill Fulcher¹, Eugene Leung², Grace Christou¹, Christopher Bredeson¹, Mitchell Sabloff¹

Affiliations

¹ Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada.
² Division of Nuclear Medicine, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada.

PMID: 32427017
DOI: 10.1080/10428194.2020.1761965

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy